MX2020010899A - Inhibidor de bromodominio. - Google Patents
Inhibidor de bromodominio.Info
- Publication number
- MX2020010899A MX2020010899A MX2020010899A MX2020010899A MX2020010899A MX 2020010899 A MX2020010899 A MX 2020010899A MX 2020010899 A MX2020010899 A MX 2020010899A MX 2020010899 A MX2020010899 A MX 2020010899A MX 2020010899 A MX2020010899 A MX 2020010899A
- Authority
- MX
- Mexico
- Prior art keywords
- methylsulfonylphenyl
- cyclopropylmethoxy
- methylisoqu
- inolin
- bromodomain inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe en la presente solicitud el inhibidor de bromodominio 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin -1-ona, que incluye sus formas cristalinas, formas amorfas, solvatos e hidratos, al igual que composiciones farmacéuticas que incluyen este inhibidor de bromodominio. En algunas formas de realización, la composición farmacéutica comprende 4-[2-(ciclopropilmetoxi)-5- metilsulfonilfenil]-2-metilisoquinolin -1-ona que ha sido procesada por medio de la micronización o la dispersión secada por pulverización. En algunas formas de realización, la composición farmacéutica además comprende por lo menos un polímero. En algunas formas de realización, las composiciones farmacéuticas comprenden una matriz de polímero sólida que comprende 4-[2-(ciclopropilmetoxi)-5-metilsulfonilfenil ]-2-metilisoquinolin-1-ona y por lo menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2-(ciclopropilmetoxi )-5-metilsulfonilfenil]-2-metilisoquinolin-1-ona son útiles para el tratamiento de cáncer o enfermedad neoplásica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010899A true MX2020010899A (es) | 2022-02-15 |
Family
ID=57143581
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013501A MX2017013501A (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
| MX2020010899A MX2020010899A (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013501A MX2017013501A (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (es) |
| EP (1) | EP3285770A4 (es) |
| JP (1) | JP2018513863A (es) |
| KR (1) | KR20170139119A (es) |
| CN (1) | CN107613981A (es) |
| AR (1) | AR104340A1 (es) |
| AU (1) | AU2016252992A1 (es) |
| BR (1) | BR112017022691A2 (es) |
| CA (1) | CA2983446C (es) |
| CL (1) | CL2017002679A1 (es) |
| CO (1) | CO2017011482A2 (es) |
| EA (1) | EA201792317A1 (es) |
| EC (1) | ECSP17071545A (es) |
| HK (1) | HK1243948A1 (es) |
| IL (1) | IL255120B (es) |
| MX (2) | MX2017013501A (es) |
| PE (1) | PE20180036A1 (es) |
| PH (1) | PH12017501933A1 (es) |
| SG (1) | SG11201708627TA (es) |
| TW (1) | TW201642860A (es) |
| WO (1) | WO2016172618A1 (es) |
| ZA (1) | ZA201707186B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMODOMAIN INHIBITOR |
| SI3532059T1 (sl) | 2016-10-27 | 2022-06-30 | Celgene Quanticel Research, Inc. | Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom |
| WO2020023438A2 (en) | 2018-07-23 | 2020-01-30 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| WO2022178226A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| PL3290407T3 (pl) * | 2013-10-18 | 2020-09-07 | Celgene Quanticel Research, Inc | Inhibitory bromodomen |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMODOMAIN INHIBITOR |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en active Application Filing
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 MX MX2017013501A patent/MX2017013501A/es active IP Right Grant
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active IP Right Grant
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 MX MX2020010899A patent/MX2020010899A/es unknown
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
-
2018
- 2018-03-14 HK HK18103550.6A patent/HK1243948A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016252992A1 (en) | 2017-11-09 |
| SG11201708627TA (en) | 2017-11-29 |
| AR104340A1 (es) | 2017-07-12 |
| IL255120B (en) | 2021-03-25 |
| CO2017011482A2 (es) | 2018-01-31 |
| CA2983446A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| EA201792317A1 (ru) | 2018-03-30 |
| PH12017501933A1 (en) | 2018-03-19 |
| TW201642860A (zh) | 2016-12-16 |
| CN107613981A (zh) | 2018-01-19 |
| ECSP17071545A (es) | 2017-12-01 |
| WO2016172618A1 (en) | 2016-10-27 |
| EP3285770A1 (en) | 2018-02-28 |
| US20160310423A1 (en) | 2016-10-27 |
| CL2017002679A1 (es) | 2018-05-25 |
| PE20180036A1 (es) | 2018-01-09 |
| KR20170139119A (ko) | 2017-12-18 |
| IL255120A0 (en) | 2017-12-31 |
| HK1243948A1 (zh) | 2018-07-27 |
| NZ736630A (en) | 2024-03-22 |
| CA2983446C (en) | 2024-04-09 |
| EP3285770A4 (en) | 2018-10-31 |
| ZA201707186B (en) | 2019-01-30 |
| MX2017013501A (es) | 2018-02-09 |
| BR112017022691A2 (pt) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501933A1 (en) | Bromodomain inhibitor | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| PH12018501340A1 (en) | Heterocyclic compounds as immunomodulators | |
| EP4285904A3 (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| CR20200545A (es) | Inhibidores magl | |
| EP3934652A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES | |
| TN2016000270A1 (en) | Heteroaryls and uses thereof. | |
| EP3530123A4 (en) | FEED COMPOSITION WITH BACILIUS SUBTILUS STEM AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF ACUTE HEPATOPANIC NECROSIS OR WHITE SPOT SYNDROME | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| EP4327887A3 (en) | Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease | |
| MY192861A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| WO2019073331A3 (en) | Pharmaceutical compositions of apremilast | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX2017001603A (es) | Derivados de piperazina como moduladores de los receptores x del higado. | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| MX2019004187A (es) | Inhibidores de bromodominios. |